Alkem Laboratories in focus after Saudi Arabia JV

Alkem Laboratories is in focus today after incorporating Alkem Pharma Company in Saudi Arabia, with chart support at 5,140 and resistance at 5,410. Alkem Laboratories Limited [ ALKEM ] is in focus today after it incorporated Alkem Pharma Company, a joint venture in Saudi Arabia, on 8 November 2026. Alkem holds 51% of it, after subscribing to 38,250 shares for SAR 3.825 million in cash. The new company will manufacture, import, market and distribute pharmaceutical and nutraceutical products in Saudi Arabia. The company calls it a strategic investment to expand its market reach. No revenue or profit impact has been disclosed, so it is not an earnings trigger. On the daily chart, the stock last closed at 5,304. The trend was sideways to bearish earlier, with the recent low near 4,800. Momentum turned positive after 22 October 2026. The relative strength index is near 60, above its own average of about 49. This suggests the recovery has strength, but the price is still below resistance. What next: support is placed at 5,140 and resistance at 5,410. A close above 5,410 may extend the recovery. A close below 5,140 may bring back the earlier weakness. Conclusion: news supports interest, but price needs to clear 5,410 first. Disclaimer: I do not hold any position in the stock discussed. This content is informational, not a recommendation. Investments in securities are subject to market risks. Read all related documents carefully before investing.